These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 10613364)

  • 1. Study documents cost reduction with outpatient enoxaparin therapy.
    Miller JL
    Am J Health Syst Pharm; 1999 Dec; 56(24):2508. PubMed ID: 10613364
    [No Abstract]   [Full Text] [Related]  

  • 2. Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation.
    Huse DM; Cummins G; Taylor DC; Russell MW
    Am J Manag Care; 2002 Jan; 8(1 Suppl):S10-6. PubMed ID: 11822346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Barriers to the use of outpatient enoxaparin therapy in patients with deep venous thrombosis.
    Shapiro NI; Spear J; Sheehy S; Brown J; Edlow JA
    Am J Emerg Med; 2005 Jan; 23(1):30-4. PubMed ID: 15672334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outpatient treatment of DVT in a 170,000-member HMO.
    Abu-Samrah S
    Manag Care; 1999 Dec; 8 Suppl():21. PubMed ID: 11729400
    [No Abstract]   [Full Text] [Related]  

  • 5. Case report: Patient adherence to drug regimens vital to treatment.
    Simmons BB; Dubreuil AL
    Am Fam Physician; 2007 Sep; 76(6):769-70. PubMed ID: 17912761
    [No Abstract]   [Full Text] [Related]  

  • 6. Out-of-hospital treatment of venous thrombosis: socioeconomic aspects and patients' quality of life.
    Bossuyt PM; van den Belt AG; Prins MH
    Haemostasis; 1998; 28 Suppl 3():100-7. PubMed ID: 10069769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reimbursement for outpatient therapy with enoxaparin.
    Dhamecha A; Yaron J
    Case Manager; 2002; 13(5):56-60; quiz 61. PubMed ID: 12239515
    [No Abstract]   [Full Text] [Related]  

  • 8. Reimbursement of enoxaparin for outpatient therapy. Proceedings of regional meetings.
    Manag Care; 1999 Dec; 8 Suppl():7-13. PubMed ID: 11729401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deep venous thrombosis: outpatient therapy with low-molecular-weight heparin.
    Tapson VF
    Manag Care; 1999 Dec; 8 Suppl():2-6. PubMed ID: 11729399
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness of enoxaparin versus low-dose heparin for prophylaxis against venous thrombosis after major trauma.
    Devlin JW; Petitta A; Shepard AD; Obeid FN
    Pharmacotherapy; 1998; 18(6):1335-42. PubMed ID: 9855335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic interchange of low-molecular-weight heparins.
    Burnakis TG
    Am J Health Syst Pharm; 2000 Oct; 57(19):1797-8; author reply 1800-2. PubMed ID: 11030034
    [No Abstract]   [Full Text] [Related]  

  • 12. Therapeutic interchange of low-molecular-weight heparins.
    Gonzalez LS
    Am J Health Syst Pharm; 2000 Oct; 57(19):1798, 1800; author reply 1800-2. PubMed ID: 11030035
    [No Abstract]   [Full Text] [Related]  

  • 13. Septic superior ophthalmic vein thrombosis: enoxaparin needs to be monitored.
    Malcolm SJ
    Clin Exp Ophthalmol; 2002 Dec; 30(6):449; author reply 449. PubMed ID: 12427245
    [No Abstract]   [Full Text] [Related]  

  • 14. Is once- or twice-a-day enoxaparin as effective as unfractionated heparin for the treatment of venous thromboembolism (VTE)?
    Marsland T; Newton W
    J Fam Pract; 2001 May; 50(5):396. PubMed ID: 11350700
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of vascular thrombosis with enoxaparin in orthotopic heart transplant patients during the early postoperative period.
    Lopshire JC; Darroca AG; Gradus-Pizlo I; O'Donnell JA
    J Heart Lung Transplant; 2001 Sep; 20(9):1025-9. PubMed ID: 11557199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery in Belgium.
    Annemans L; Minjoulat-Rey MC; De Knock M; Vranckx K; Czarka M; Gabriel S; Haentjens P
    Acta Clin Belg; 2004; 59(6):346-57. PubMed ID: 15819379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost comparison of at-home treatment of deep venous thrombosis with low molecular weight heparin to inpatient treatment with unfractionated heparin.
    Smith BJ; Weekley JS; Pilotto L; Howe T; Beven R
    Intern Med J; 2002; 32(1-2):29-34. PubMed ID: 11783670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery.
    Sullivan SD; Davidson BL; Kahn SR; Muntz JE; Oster G; Raskob G
    Pharmacoeconomics; 2004; 22(9):605-20. PubMed ID: 15209529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LMW heparins: from transition to fruition.
    Check W
    CAP Today; 1999 Jun; 13(6):1, 62, 66-7; passim. PubMed ID: 10539128
    [No Abstract]   [Full Text] [Related]  

  • 20. Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program.
    Bookhart BK; Haskell L; Bamber L; Wang M; Schein J; Mody SH
    J Med Econ; 2014 Oct; 17(10):691-5. PubMed ID: 25065536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.